Noninfectious uveitis is known for its chronic and cumulative nature. It is often associated with diagnostic and therapeutic difficulties. It causes significant vision loss in young patients, making them incapable of maintaining an active work life. Diagnosis and treatment require cooperation between different specialists and are based on multiple blood tests and other diagnostic tests. This article presents medical indications and the safety and efficacy of adalimumab, a tumor necrosis factor inhibitor and the first biological drug used in ophthalmology. Adalimumab is an important therapeutic option for the treatment of intermediate, posterior, and pan-uveitis, enabling patients to obtain and maintain long-term disease control during simultaneous corticosteroid/immunomodulatory therapy or without it.
PL
Nieinfekcyjne zapalenia błony naczyniowej (NZBN) stanowią problem diagnostyczny i terapeutyczny, mają przewlekły i kumulacyjny charakter, a także są przyczyną znaczącej utraty funkcji wzroku u młodych osób, uniemożliwiającej aktywność zawodową. Diagnostyka i leczenie wymagają współpracy specjalistów z różnych dziedzin i opierają się na licznych badaniach laboratoryjnych i obrazowych. Praca przedstawia wskazania, efektywność i bezpieczeństwo terapii pierwszym lekiem biologicznym stosowanym w okulistyce, jakim jest inhibitor czynnika martwicy guza α, adalimumab. Może być on uznany za istotną opcję terapeutyczną w leczeniu zapalenia błony naczyniowej części pośredniej i tylnej, a także zapalenia wszystkich części błony naczyniowej, ponieważ pozwala pacjentom na osiągnięcie i utrzymanie długotrwałej kontroli nad chorobą przy jednoczesnej terapii glikokortykosteroidami czy lekami immunomodulującymi lub jej braku.
Introduction: The diagnostic and therapeutic recommendations have been changing over the years to improve treatment outcomes and quality of life of Head and Neck Cancer (HNC) patients. Aim: The aim of this study was to present currently recommended Head and Neck Cancer treatment guidelines based on the literature review with particular emphasis on novel approaches the NCCN algorithms. Material and methods: The review of literature covering articles published in the last five years and pointing out essential changes in HNC treatment regarding evidence based medicine. The study focused on the analysis of novel approaches for the particular primaries, the implementation of biological therapies and personalized cancer therapies. Results: Updates in the oncological NCCN guidelines for all ENT primaries except major salivary glands and subglottis are based on knowledge derived from the basic sciences, clinical trials and the best evidence available currently. The latest recommendations emphasize value of biological therapies use.
Introduction: The diagnostic and therapeutic recommendations have been changing over the years to improve treatment outcomes and quality of life of Head and Neck Cancer (HNC) patients. Aim: The aim of this study was to present currently recommended Head and Neck Cancer treatment guidelines based on the literature review with particular emphasis on novel approaches the NCCN algorithms. Material and methods: The review of literature covering articles published in the last five years and pointing out essential changes in HNC treatment regarding evidence based medicine. The study focused on the analysis of novel approaches for the particular primaries, the implementation of biological therapies and personalized cancer therapies. Results: Updates in the oncological NCCN guidelines for all ENT primaries except major salivary glands and subglottis are based on knowledge derived from the basic sciences, clinical trials and the best evidence available currently. The latest recommendations emphasize value of biological therapies use.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.